Azitra, Inc. Files 8-K: Delisting Notice

Ticker: AZTR · Form: 8-K · Filed: Oct 3, 2025 · CIK: 1701478

Sentiment: bearish

Topics: delisting, listing-standards, regulatory-filing

TL;DR

Azitra's in trouble, might get delisted. Big red flag.

AI Summary

Azitra, Inc. filed an 8-K on October 3, 2025, reporting a notice of delisting or failure to satisfy continued listing rules, along with other events and financial statements. The company, incorporated in Delaware with its principal executive offices in Branford, CT, is involved in pharmaceutical preparations.

Why It Matters

This filing indicates potential issues with Azitra, Inc.'s continued listing on an exchange, which could significantly impact its stock value and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards is a severe warning sign for a company's financial health and future viability.

Key Players & Entities

FAQ

What specific rule or standard has Azitra, Inc. failed to satisfy, leading to this delisting notice?

The filing does not specify the exact rule or standard that Azitra, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on October 1, 2025.

What is Azitra, Inc.'s primary business as indicated by its SIC code?

Azitra, Inc.'s primary business is Pharmaceutical Preparations, as indicated by its SIC code 2834.

Where are Azitra, Inc.'s principal executive offices located?

Azitra, Inc.'s principal executive offices are located at 21 Business Park Drive, Suite 6, Branford, CT 06405.

What is the filing date of this 8-K report?

This 8-K report was filed on October 3, 2025.

Filing Stats: 1,004 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2025-10-03 16:59:09

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AZITRA, INC. Dated: October 3, 2025 By: /s/ Francisco Salva Name: Francisco Salva Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing